Fairchem Organics Ltd (FAIRCHEMOR)

Chemicals · Chemicals · NSE · Updated 2 September 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹666.7 ↓ 14.79% (1Y)

🎯 Key Takeaways

Fairchem Organics is in a high-growth phase driven by organic expansion and strategic capacity additions, though profitability remains constrained by margin pressures and delayed commercialization of key products like Isostearic Acid. The company is transitioning from early-stage scale-up to structured growth with a focus on export diversification and backward integration, but execution risks persist due to regulatory and input cost headwinds.
Revenue grew 50.6% QoQ to ₹176 in Q1FY27.
⚠️ 1) Margin pressure from inverted duties and geopolitical trade risks remains unaddressed despite export growth ambitions. 2) Delays in commercializing

Market Cap

₹840

P/E Ratio

58.9

P/B Ratio

3.19

ROE

5.5%

ROCE

6.9%

Debt/Equity

0.32

Div Yield

0.15%

Promoter

63.3%

✨ Ask AI About FAIRCHEMOR 📊 Interactive Charts

📖 The Story

Fairchem Organics is in a high-growth phase driven by organic expansion and strategic capacity additions, though profitability remains constrained by margin pressures and delayed commercialization of key products like Isostearic Acid. The company is transitioning from early-stage scale-up to structured growth with a focus on export diversification and backward integration, but execution risks persist due to regulatory and input cost headwinds.

📰 What's Happening

In Q1 FY27 (July 2026 filing), revenue surged 34.3% YoY to ₹1,761 crores with PAT at ₹100 crores and EBITDA margin expanding to 10.16%, up from ₹10 crores net profit in the prior quarter. Management highlighted export growth potential from US tariff reductions and proposed EU/UK FTAs, targeting export share to rise from 25% to 50%. A ₹34 crore buyback was completed in Q1 FY26, and shareholders approved all AGM resolutions including reappointments and dividend. Capacity expansion to 40,000 MT oleochemicals is underway with 70-75% utilization targeted by FY27, though Isostearic Acid ramp-up remains delayed due to cosmetics market entry barriers.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	112	100	117	176
Operating Profit	1	1	5	15
OPM %	1.3%	1.4%	4.5%	8.6%
Net Profit	1	-0	4	10
EPS	₹0.59	₹-0.07	₹2.85	₹7.95

Revenue has grown sequentially from ₹100 crores in Dec 2025 to ₹117 crores in Mar 2026, then sharply to ₹176 crores in Jun 2026, indicating accelerating demand. However, net profit improved from near breakeven to ₹10 crores in Jun 2026, while margins remain thin at 8.6% operating and 10.14% EBITDA, reflecting persistent cost pressures. Despite strong top-line growth, profitability has not yet translated into sustained earnings visibility, with PAT margin expanding only modestly from 1.3% to 10.16% over multiple quarters.

🔮 Management Outlook & What's Next

Management expects 5-7% quarterly revenue growth and 15-20% YoY growth, driven by export expansion, forward integration into value-added oleochemicals, and new 40,000 MT capacity. They emphasize sustainable growth, regulatory advantages in key markets, and cost optimization through product upgradation and geographical diversification. No debt-funded expansion is planned, aligning with their organic growth mandate, though timelines for Isostearic Acid commercialization remain uncertain.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

Item	Mar 2025	Mar 2025	Mar 2026	Mar 2026
Equity Capital	13	13	13	13
Reserves	285	289	281	250
Borrowings	44	63	54	84
Total Liabilities	383	402	388	391
Fixed Assets	191	201	199	196
Investments	0	0	0	0
Total Assets	383	402	388	391

The balance sheet shows stable equity at ₹13 crores with reserves growing from ₹250 to ₹281 crores between Mar 2025 and Mar 2026, indicating retained earnings accumulation. Borrowings have declined from ₹63 to ₹54 crores, suggesting active deleveraging or reduced reliance on external financing. Total assets remain flat around ₹388-391 crores, reflecting capital-light growth with minimal reinvestment disclosed so far, despite capacity expansion plans.

💰 Cash Flow Statement (₹ Cr)

Item	Mar 2026
Operating	+42
Investing	-14
Financing	-28
Net Cash Flow	+0

👥 Shareholding Pattern

Category	Q3FY26	Q4FY26	Q1FY27
Promoters	61.2%	63.3%	63.3%
FII	6.3%	6.3%	6.3%
DII	5.4%	4.0%	2.8%
Public	18.4%	17.8%	19.1%
# Shareholders	32,298	26,622	25,690

Promoter holding remains stable at 63.26% over recent quarters, indicating confidence in long-term prospects. FII ownership is modest at 6.34-6.35%, while DII participation has declined from 5.42% to 2.80%, suggesting reduced institutional interest or reclassification. The sharp drop in public float and rising shareholder count (from 17,842 to 25,690) may reflect retail investor interest, but foreign institutional inflows remain limited.

⚖️ Peer Comparison — Chemicals

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
PIDILITIND	1.67 L Cr	63.2	33.4%	24.7%	0.01
SRF	76,535	35.4	15.6%	15.4%	0.36
LINDEINDIA	54,418	99.6	17.5%	12.8%	0.00
FLUOROCHEM	52,063	85.1	9.6%	7.7%	0.34
NAVINFLUOR	44,292	56.0	22.2%	19.9%	0.31
GODREJIND	38,842	33.0	9.2%	19.8%	4.57
HSCL	34,339	42.7	20.7%	17.1%	0.16
DEEPAKNTR	24,328	31.1	15.3%	13.4%	0.26
AETHER	22,349	94.8	13.8%	10.6%	0.08
AARTIIND	19,030	35.8	9.2%	9.5%	0.68

🔗 Peer Stock Analyses

PIDILITIND SRF LINDEINDIA FLUOROCHEM NAVINFLUOR

⚠️ Risk Factors

1) Margin pressure from inverted duties and geopolitical trade risks remains unaddressed despite export growth ambitions. 2) Delays in commercializing Isostearic Acid for cosmetics — a high-margin segment — could stall value capture. 3) Export growth depends on unconfirmed FTAs; no binding agreements disclosed. 4) Capacity expansion targets may strain working capital if demand softens or input costs rise, with no debt financing planned to buffer volatility.

📋 Recent Filings

🧠 Analyst's Read

Fairchem Organics is executing a capital-efficient growth strategy with improving top-line momentum, but profitability and margin expansion remain fragile amid external cost pressures and delayed product ramp-ups. Investors should monitor export order inflows, Isostearic Acid commercialization timelines, and quarterly margin trends for early signs of sustainable earnings quality.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on FAIRCHEMOR

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-02.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when FAIRCHEMOR files new disclosures

Track FAIRCHEMOR filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track FAIRCHEMOR — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd